title: Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer.
abstract: OBJECTIVE
  To compare the survival of patients with locally advanced non-small cell lung cancer treated with single-agent vindesine, thoracic radiotherapy, or both treatment modalities.
  
  
  METHODS
  Randomized, prospective, phase III trial.
  
  
  METHODS
  Multi-institutional, university-based national cooperative oncology group.
  
  
  METHODS
  The study included 319 patients with locally advanced, unresectable non-small cell lung cancer who had no evidence of extrathoracic metastases. All patients were ambulatory and had measurable disease. Some patients could not have surgery because of coexisting medical conditions.
  
  
  METHODS
  Patients were randomly assigned to receive vindesine, 3 mg/m2 body surface area weekly; standard thoracic radiotherapy, 60 Gy over 6 weeks; or both vindesine and thoracic radiotherapy. Vindesine was administered for 6 weeks and then every other week to patients who had no disease progression. Patients who developed progressive disease while receiving vindesine or radiotherapy alone were crossed over to radiotherapy or vindesine, respectively. Response assessment took place at week 6.
  
  
  RESULTS
  The overall response rate was superior in the radiotherapy arms (radiotherapy alone, 30%; radiotherapy plus vindesine, 34%; vindesine alone, 10%; P = 0.001). However, with a minimum follow-up of 42 months, no improvement in survival has been seen with radiotherapy. The median survival was 8.6 months for patients receiving radiotherapy alone, 9.4 months for those receiving radiotherapy plus vindesine, and 10.1 months for those receiving vindesine (P = 0.58). Radiotherapy also failed to improve long-term survival. The 5-year survivals were 3%, 3%, and 1%, respectively (P = 0.56).
  
  
  CONCLUSIONS
  Patients with non-small cell lung cancer who have inoperable, nonmetastatic disease gain no clinically meaningful survival advantage with immediate thoracic irradiation, even when modern megavoltage radiation therapy techniques and equipment are used.
authors.affiliation: Vanderbilt University, Nashville, Tennessee.
authors.forename: D H
authors.initials: DH
authors.lastname: Johnson
authors.forename: L H
authors.initials: LH
authors.lastname: Einhorn
authors.forename: A
authors.initials: A
authors.lastname: Bartolucci
authors.forename: R
authors.initials: R
authors.lastname: Birch
authors.forename: G
authors.initials: G
authors.lastname: Omura
authors.forename: C A
authors.initials: CA
authors.lastname: Perez
authors.forename: F A
authors.initials: FA
authors.lastname: Greco
mesh_terms: D000230:Adenocarcinoma / Q000532:radiotherapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D018288:Carcinoma, Small Cell / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011832:Radiation Injuries / Q000453:epidemiology; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D014751:Vindesine / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D014751:Vindesine